Optimizing Patient Selection, Dosing & Trial Design to Set Up ADC Clinical Development for Success - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Optimizing Patient Selection, Dosing & Trial Design to Set Up ADC Clinical Development for Success

11:00 am - Tuesday 13th October 2026

Investigating ADC case studies in early clinical development to understand and compare how ADC preclinical profiles translate to patient impact
Breaking down strategies from case study lessons to best set up early ADC clinical development for success through dosing, biomarker and trial design approaches
Laying out comprehensive preclinical data of KIVU-107 to understand approach to clinical trials for a low DAR ADC

Speakers:

Mohit Trikha

Mohit Trikha

Chief Executive Officer

Kivu BioScience, Inc.